Lyra Therapeutics, Inc.
LYRA
Rank in Stocks
#31526
Lyra Therapeutics, Inc. operates as a clinical-stage biotechnology company,... Lyra Therapeutics, Inc. operates as a clinical-stage biotechnology company, primarily focused on the creation and commercialization of anti-inflammatory treatments for individuals suffering from chronic rhinosinusitis (CRS). The company's unique technological approach allows for the direct delivery of therapeutic agents to the targeted tissue, ensuring prolonged efficacy from a singular dose. Its pipeline features several promising candidates, including LYR-210, an anti-inflammatory implantable drug matrix currently in Phase III clinical trials for CRS. Additionally, LYR-220 is under development for CRS patients who have not responded to previous medical treatments and still require intervention for their symptoms. Lyra has forged a partnership with LianBio Inflammatory Limited to facilitate the development and market entry of LYR-210 throughout specific Asian regions, encompassing mainland China, Hong Kong, Taiwan, Macau, South Korea, Singapore, and Thailand. Established in 2005, the company was initially known as 480 Biomedical, Inc. before adopting the name Lyra Therapeutics, Inc. in July 2018. Its corporate headquarters are located in Watertown, Massachusetts.
Share Price
$0.19
Last synced: 2026-11-09
Market Cap
$2.95M
Change (1 day)
0.00%
Change (1 year)
-95.10%
Country
Stock data: Financial Modeling PrepΒ·Updated Β·Not investment adviceΒ·How we calculate this
Trade Lyra Therapeutics, Inc. (LYRA)
Category
Healthcare
EPS for Lyra Therapeutics, Inc. (LYRA)
EPS as of December 2025 TTM: $-18.62
According to Lyra Therapeutics, Inc.'s latest financial reports, its current EPS (TTM) is $-18.62. At the end of 2025 the company had an EPS of $-18.62, a decrease compared to its 2024 EPS of $-1.43.
EPS history for Lyra Therapeutics, Inc. from 2018 to 2026
EPS at the end of each year
| Year | EPS | Change |
|---|---|---|
| 2026 (TTM) | $-18.62 | 0.00% |
| 2025 | $-18.62 | 1,202.10% |
| 2024 | $-1.43 | 13.49% |
| 2023 | $-1.26 | -31.15% |
| 2022 | $-1.83 | -45.37% |
| 2021 | $-3.35 | 29.34% |
| 2020 | $-2.59 | -95.86% |
| 2019 | $-62.50 | 6,277.55% |
| 2018 | $-0.98 | 0.00% |
EPS for similar companies or competitors
| Company | EPS | EPS Difference | Country |
|---|---|---|---|
| $15.66 | -184.10% |
US
|
|
| $-7.07 | -62.03% |
US
|
|
| $-5.29 | -71.59% |
AU
|
|
| $12.88 | -169.17% |
BE
|
|
| $21.56 | -215.79% |
NL
|
Questions about Lyra Therapeutics, Inc.'s earnings per share (EPS)
What is Lyra Therapeutics, Inc.'s earnings per share (EPS)?
Lyra Therapeutics, Inc.'s earnings per share (EPS) over the last twelve months is $-18.62, as of Dec 2025.
What was Lyra Therapeutics, Inc.'s earnings per share (EPS) in 2025?
In 2025, Lyra Therapeutics, Inc.'s earnings per share (EPS) was $-18.62, compared with $-1.43 in 2024.
How has Lyra Therapeutics, Inc.'s earnings per share (EPS) changed since 2020?
From 2020 to 2025, Lyra Therapeutics, Inc.'s earnings per share (EPS) was highest in 2023 ($-1.26) and lowest in 2025 ($-18.62).
How does Lyra Therapeutics, Inc.'s earnings per share (EPS) compare with similar companies?
Lyra Therapeutics, Inc.'s earnings per share (EPS) ($-18.62) is lower than that of all 5 similar companies listed above. The highest among them is Argenx SE, with $21.56.